Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2013, 48193-48197 [2013-19046]

Download as PDF Federal Register / Vol. 78, No. 152 / Wednesday, August 7, 2013 / Notices To submit comments: Send them to: By e-mail ...... pubcommentees.enrd@usdoj.gov. Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611. By mail ......... Under section 7003(d) of RCRA, a commenter may request an opportunity for a public meeting in the affected area. During the public comment period, the Consent Decree may be examined and downloaded at this Justice Department Web site: http:// www.usdoj.gov/enrd/ Consent_Decrees.html. We will provide a paper copy of the Consent Decree upon written request and payment of reproduction costs. Please mail your request and payment to: Consent Decree Library, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611. Please enclose a check or money order for $8.25 (25 cents per page reproduction cost) payable to the United States Treasury. Maureen M. Katz, Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. 2013–19005 Filed 8–6–13; 8:45 am] BILLING CODE 4410–15–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–365] Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2013 Drug Enforcement Administration (DEA), Department of Justice. ACTION: Notice. AGENCY: This notice establishes final adjusted 2013 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA) and assessment of annual needs for the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, as well as the 2013 aggregate production quotas for three recently temporarily controlled substances. FOR FURTHER INFORMATION CONTACT: John W. Partridge, Executive Assistant, Office of Diversion Control, Drug Enforcement Administration, 8701 Morrissette Drive, mstockstill on DSK4VPTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 17:03 Aug 06, 2013 Jkt 229001 Springfield, VA 22152, Telephone: (202) 307–7165. SUPPLEMENTARY INFORMATION: Background Section 306 of the CSA (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II and for ephedrine, pseudoephedrine, and phenylpropanolamine. This responsibility has been delegated to the Administrator of the DEA through 28 CFR 0.100. The Administrator, in turn, has redelegated this function to the Deputy Administrator, pursuant to 28 CFR 0.104. DEA published the 2013 established aggregate production quotas for controlled substances in Schedules I and II and assessment of annual needs for the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine in the Federal Register (77 FR 59980) on October 1, 2012. That notice stated that the Deputy Administrator would adjust, as needed, the established aggregate production quotas in 2013 as provided for in 21 CFR 1303.13 and 21 CFR 1315.13. The 2013 proposed adjusted aggregate production quotas for controlled substances in Schedules I and II and assessment of annual needs for the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine were subsequently published in the Federal Register on June 20, 2013, (78 FR 37237) in consideration of the outlined criteria. All interested persons were invited to comment on or object to the proposed adjusted aggregate production quotas and assessment of annual needs on or before July 22, 2013. Analysis for Final Adjusted 2013 Aggregate Production Quotas and Assessment of Annual Needs Consideration has been given to the criteria outlined in the June 20, 2013, notice of proposed adjusted aggregate production quotas and assessment of annual needs, in accordance with 21 CFR 1303.13 and 21 CFR 1315.13. Six companies submitted timely comments regarding a total of 30 Schedule I and II controlled substances. Comments received proposed that the aggregate production quotas for 2-(2,5-Dimethoxy4-(n)-propylphenyl)ethanamine (2C–P); 2-(2,5-Dimethoxy-4ethylphenyl)ethanamine (2C–E); 2-(2,5Dimethoxy-4-methylphenyl)ethanamine (2C–D); 2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine (2C–N); 2-(2,5Dimethoxyphenyl)ethanamine (2C–H); 2-(4-Chloro-2,5dimethoxyphenyl)ethanamine (2C–C); PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 48193 2-(4-Iodo-2,5dimethoxyphenyl)ethanamine (2C–I); 2[4-(Ethylthio)-2,5dimethoxyphenyl]ethanamine (2C–T–2); 2-[4-(Isopropylthio)-2,5dimethoxyphenyl]ethanamine (2C–T–4); 3,4-Methylenedioxymethamphetamine (MDMA); 4-Anilino-N-phenethyl-4piperidine (ANPP); amphetamine (for sale); codeine (for conversion); dihydromorphine; diphenoxylate (for sale); gamma hydroxybutyric acid; hydrocodone; hydromorphone; levomethorphan; methadone; methadone intermediate; methylphenidate; morphine (for conversion); morphine (for sale); oxycodone (for sale); oripavine; oxymorphone (for conversion); oxymorphone (for sale); phenylacetone; and sufentanil were insufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, for export requirements, and for the establishment and maintenance of reserve stocks. One manufacturer commented that the APQ for thebaine was insufficient; however, that commenter was referring to a need for procurement quota for thebaine, which does not directly impact the APQ and, thus, was not considered. DEA did not previously propose adjustments to the 2013 assessment of annual needs for ephedrine, pseudoephedrine, and phenylpropanolamine and received no comments concerning such. DEA has taken into consideration the above comments along with the relevant 2012 year-end inventories, initial 2013 manufacturing quotas and import quotas, 2013 export requirements, actual and projected 2013 sales, research and product development requirements, and additional applications received. Based on all of the above, the Deputy Administrator has determined that the proposed adjusted 2013 aggregate production quotas and assessment of annual needs for dihydromorphine; diphenoxylate (for sale); gamma hydroxybutyric acid; hydromorphone; levomethorphan; morphine (for sale); oxymorphone (for sale); phenylacetone; psilocyn; sufentanil; ephedrine (for sale); phenylpropanolamine (for conversion); and pseudoephedrine (for sale) required additional consideration and hereby further adjusts the 2013 aggregate production quotas for those substances. Regarding 2-(2,5-Dimethoxy-4-(n)propylphenyl)ethanamine (2C–P); 2(2,5-Dimethoxy-4ethylphenyl)ethanamine (2C–E); 2-(2,5Dimethoxy-4-methylphenyl)ethanamine (2C–D); 2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine (2C–N); 2-(2,5Dimethoxyphenyl)ethanamine (2C–H); E:\FR\FM\07AUN1.SGM 07AUN1 48194 Federal Register / Vol. 78, No. 152 / Wednesday, August 7, 2013 / Notices 2-(4-Chloro-2,5dimethoxyphenyl)ethanamine (2C–C); 2-(4-Iodo-2,5dimethoxyphenyl)ethanamine (2C–I); 2[4-(Ethylthio)-2,5dimethoxyphenyl]ethanamine (2C–T–2); 2-[4-(Isopropylthio)-2,5dimethoxyphenyl]ethanamine (2C–T–4); 3,4-Methylenedioxymethamphetamine (MDMA); 4-Anilino-N-phenethyl-4piperidine (ANPP); amphetamine (for sale); codeine (for conversion); hydrocodone; methadone; methadone intermediate; methylphenidate; morphine (for conversion); oxycodone (for sale); oripavine; and oxymorphone (for conversion), the Deputy Administrator hereby determines that the proposed adjusted 2013 aggregate production quotas and assessment of annual needs for these substances and List I chemicals as published on June 20, 2013, (78 FR 37237) are sufficient to meet the current 2013 estimated medical, scientific, research, and industrial needs of the United States and to provide for adequate inventories. As described in the previously published notice establishing the 2013 aggregate production quotas and assessment of annual needs, DEA has specifically considered that inventory allowances granted to individual manufacturers may not always result in the availability of sufficient quantities to maintain an adequate reserve stock pursuant to 21 U.S.C. 826(a), as intended. See 21 CFR 1303.24. This would be concerning if a natural disaster or other unforeseen event resulted in substantial disruption to the amount of controlled substances available to provide for legitimate public need. As such, DEA has included in all proposed revised Schedule II aggregate production quotas, and certain Schedule I aggregate production quotas, an additional 25% of the estimated medical, scientific, and research needs as part of the amount necessary to ensure the establishment and maintenance of reserve stocks. The resulting adjusted established aggregate production quotas will reflect these included amounts. This action will not affect the ability of manufacturers to maintain inventory allowances as specified by regulation. DEA expects that maintaining this reserve in certain established aggregate production quotas will mitigate adverse public effects if an unforeseen event resulted in substantial disruption to the amount of controlled substances available to provide for legitimate public need, as determined by DEA. DEA does not anticipate utilizing the reserve in the absence of these circumstances. Pursuant to the above, the Deputy Administrator hereby finalizes the 2013 aggregate production quotas for the following Schedule I and II controlled substances and the 2013 assessment of annual needs for the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows: Final adjusted 2013 quotas Basic class Temporarily Scheduled Substances (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR–144) ............................................................................... [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11) .................................................................. N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48) ..................................................................................................... 15 g 15 g 15 g mstockstill on DSK4VPTVN1PROD with NOTICES Schedule I 1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ........................................................................................................................ 1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ....................................................................................................................... 1-[1-(2-Thienyl)cyclohexyl]piperidine ............................................................................................................................................... 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH–200) .......................................................................................................... 1-Butyl-3-(1-naphthoyl)indole (JWH–073) ....................................................................................................................................... 1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR–18 and RCS–8) ..................................................................................... 1-Hexyl-3-(1-naphthoyl)indole (JWH–019) ...................................................................................................................................... 1-Methyl-4-phenyl-4-propionoxypiperidine ....................................................................................................................................... 1-Pentyl-3-(1-naphthoyl)indole (JWH–018 and AM678) ................................................................................................................. 1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH–203) ....................................................................................................................... 1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH–250) ................................................................................................................... 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH–398) ....................................................................................................................... 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH–122) ...................................................................................................................... 1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR–19, RCS–4) ............................................................................................................... 1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH–081) .................................................................................................................. 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C–P) .............................................................................................................. 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E) ...................................................................................................................... 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D) ................................................................................................................... 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C–N) ..................................................................................................................... 2-(2,5-Dimethoxyphenyl)ethanamine (2C–H) .................................................................................................................................. 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C) .................................................................................................................... 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I) ......................................................................................................................... 2,5-Dimethoxy-4-ethylamphetamine (DOET) .................................................................................................................................. 2,5-Dimethoxy-4-n-propylthiophenethylamine ................................................................................................................................. 2,5-Dimethoxyamphetamine ............................................................................................................................................................ 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–2) ........................................................................................................... 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–4) .................................................................................................... 3,4,5-Trimethoxyamphetamine ........................................................................................................................................................ 3,4-Methylenedioxyamphetamine (MDA) ........................................................................................................................................ 3,4-Methylenedioxymethamphetamine (MDMA) ............................................................................................................................. 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ......................................................................................................................... 3,4-Methylenedioxy-N-methylcathinone (methylone) ...................................................................................................................... 3,4-Methylenedioxypyrovalerone (MDPV) ....................................................................................................................................... 3-Methylfentanyl ............................................................................................................................................................................... 3-Methylthiofentanyl ......................................................................................................................................................................... VerDate Mar<15>2010 17:03 Aug 06, 2013 Jkt 229001 PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 E:\FR\FM\07AUN1.SGM 07AUN1 45 45 5 45 45 45 45 2 45 45 45 45 45 45 45 15 15 15 15 15 15 15 12 12 12 15 15 12 30 50 24 35 25 2 2 g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g Federal Register / Vol. 78, No. 152 / Wednesday, August 7, 2013 / Notices Final adjusted 2013 quotas Basic class mstockstill on DSK4VPTVN1PROD with NOTICES 48195 4-Bromo-2,5-dimethoxyamphetamine (DOB) .................................................................................................................................. 4-Bromo-2,5-dimethoxyphenethylamine (2–CB) ............................................................................................................................. 4-Methoxyamphetamine .................................................................................................................................................................. 4-Methyl-2,5-dimethoxyamphetamine (DOM) .................................................................................................................................. 4-Methylaminorex ............................................................................................................................................................................ 4-Methyl-N-methylcathinone (mephedrone) .................................................................................................................................... 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ..................................................................................................... 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP–47, 497 C8-homolog) ..................... 5-Methoxy-3,4-methylenedioxyamphetamine .................................................................................................................................. 5-Methoxy-N,N-diisopropyltryptamine .............................................................................................................................................. 5-Methoxy-N,N-dimethyltryptamine ................................................................................................................................................. Acetyl-alpha-methylfentanyl ............................................................................................................................................................. Acetyldihydrocodeine ....................................................................................................................................................................... Acetylmethadol ................................................................................................................................................................................ Allylprodine ...................................................................................................................................................................................... Alphacetylmethadol .......................................................................................................................................................................... Alpha-ethyltryptamine ...................................................................................................................................................................... Alphameprodine ............................................................................................................................................................................... Alphamethadol ................................................................................................................................................................................. Alpha-methylfentanyl ....................................................................................................................................................................... Alpha-methylthiofentanyl .................................................................................................................................................................. Alpha-methyltryptamine (AMT) ........................................................................................................................................................ Aminorex .......................................................................................................................................................................................... Benzylmorphine ............................................................................................................................................................................... Betacetylmethadol ........................................................................................................................................................................... Beta-hydroxy-3-methylfentanyl ........................................................................................................................................................ Beta-hydroxyfentanyl ....................................................................................................................................................................... Betameprodine ................................................................................................................................................................................. Betamethadol ................................................................................................................................................................................... Betaprodine ...................................................................................................................................................................................... Bufotenine ........................................................................................................................................................................................ Cathinone ......................................................................................................................................................................................... Codeine-N-oxide .............................................................................................................................................................................. Desomorphine .................................................................................................................................................................................. Diethyltryptamine ............................................................................................................................................................................. Difenoxin .......................................................................................................................................................................................... Dihydromorphine .............................................................................................................................................................................. Dimethyltryptamine .......................................................................................................................................................................... Gamma-hydroxybutyric acid ............................................................................................................................................................ Heroin .............................................................................................................................................................................................. Hydromorphinol ................................................................................................................................................................................ Hydroxypethidine ............................................................................................................................................................................. Ibogaine ........................................................................................................................................................................................... Lysergic acid diethylamide (LSD) .................................................................................................................................................... Marihuana ........................................................................................................................................................................................ Mescaline ......................................................................................................................................................................................... Methaqualone .................................................................................................................................................................................. Methcathinone ................................................................................................................................................................................. Methyldihydromorphine .................................................................................................................................................................... Morphine-N-oxide ............................................................................................................................................................................ N,N-Dimethylamphetamine .............................................................................................................................................................. N-Benzylpiperazine .......................................................................................................................................................................... N-Ethylamphetamine ....................................................................................................................................................................... N-Hydroxy-3,4-methylenedioxyamphetamine .................................................................................................................................. Noracymethadol ............................................................................................................................................................................... Norlevorphanol ................................................................................................................................................................................. Normethadone ................................................................................................................................................................................. Normorphine .................................................................................................................................................................................... Para-fluorofentanyl ........................................................................................................................................................................... Phenomorphan ................................................................................................................................................................................ Pholcodine ....................................................................................................................................................................................... Properidine ....................................................................................................................................................................................... Psilocybin ......................................................................................................................................................................................... Psilocyn ............................................................................................................................................................................................ Tetrahydrocannabinols .................................................................................................................................................................... Thiofentanyl ..................................................................................................................................................................................... Tilidine .............................................................................................................................................................................................. Trimeperidine ................................................................................................................................................................................... 12 12 88 25 12 25 68 53 12 12 10 2 2 2 2 2 12 2 2 2 2 12 12 2 2 2 2 2 2 2 3 12 602 5 12 50 3,990,000 18 67,500,000 25 54 2 5 30 21,000 13 10 14 2 655 12 15 12 12 2 52 2 18 2 2 2 2 10 12 491,000 2 10 2 g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g Schedule II 1-Phenylcyclohexylamine ................................................................................................................................................................ 1-Piperdinocyclohexanecarbonitrile ................................................................................................................................................. VerDate Mar<15>2010 17:03 Aug 06, 2013 Jkt 229001 PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 E:\FR\FM\07AUN1.SGM 07AUN1 3g 21 g 48196 Federal Register / Vol. 78, No. 152 / Wednesday, August 7, 2013 / Notices Final adjusted 2013 quotas Basic class 4-Anilino-N-phenethyl-4-piperidine (ANPP) ..................................................................................................................................... Alfentanil .......................................................................................................................................................................................... Alphaprodine .................................................................................................................................................................................... Amobarbital ...................................................................................................................................................................................... Amphetamine (for conversion) ........................................................................................................................................................ Amphetamine (for sale) ................................................................................................................................................................... Carfentanil ........................................................................................................................................................................................ Cocaine ............................................................................................................................................................................................ Codeine (for conversion) ................................................................................................................................................................. Codeine (for sale) ............................................................................................................................................................................ Dextropropoxyphene ........................................................................................................................................................................ Dihydrocodeine ................................................................................................................................................................................ Diphenoxylate .................................................................................................................................................................................. Ecgonine .......................................................................................................................................................................................... Ethylmorphine .................................................................................................................................................................................. Fentanyl ........................................................................................................................................................................................... Glutethimide ..................................................................................................................................................................................... Hydrocodone (for sale) .................................................................................................................................................................... Hydromorphone ............................................................................................................................................................................... Isomethadone .................................................................................................................................................................................. Levo-alphacetylmethadol (LAAM) .................................................................................................................................................... Levomethorphan .............................................................................................................................................................................. Levorphanol ..................................................................................................................................................................................... Lisdexamfetamine ............................................................................................................................................................................ Meperidine ....................................................................................................................................................................................... Meperidine Intermediate-A .............................................................................................................................................................. Meperidine Intermediate-B .............................................................................................................................................................. Meperidine Intermediate-C .............................................................................................................................................................. Metazocine ....................................................................................................................................................................................... Methadone (for sale) ....................................................................................................................................................................... Methadone Intermediate .................................................................................................................................................................. Methamphetamine ........................................................................................................................................................................... 2,250,000 38,250 3 9 22,875,000 47,186,000 6 240,000 81,250,000 49,506,250 19 250,000 887,500 144,000 3 2,108,750 3 99,625,000 6,750,000 5 4 195 4,500 21,000,000 6,875,000 6 11 6 6 33,125,000 40,500,000 3,912,500 g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g [987,500 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,863,750 grams for methamphetamine mostly for conversion to a schedule III product; and 61,250 grams for methamphetamine (for sale)] Methylphenidate ............................................................................................................................................................................... Morphine (for conversion) ................................................................................................................................................................ Morphine (for sale) .......................................................................................................................................................................... Nabilone ........................................................................................................................................................................................... Noroxymorphone (for conversion) ................................................................................................................................................... Noroxymorphone (for sale) .............................................................................................................................................................. Opium (powder) ............................................................................................................................................................................... Opium (tincture) ............................................................................................................................................................................... Oripavine .......................................................................................................................................................................................... Oxycodone (for conversion) ............................................................................................................................................................ Oxycodone (for sale) ....................................................................................................................................................................... Oxymorphone (for conversion) ........................................................................................................................................................ Oxymorphone (for sale) ................................................................................................................................................................... Pentobarbital .................................................................................................................................................................................... Phenazocine .................................................................................................................................................................................... Phencyclidine ................................................................................................................................................................................... Phenmetrazine ................................................................................................................................................................................. Phenylacetone ................................................................................................................................................................................. Racemethorphan ............................................................................................................................................................................. Remifentanil ..................................................................................................................................................................................... Secobarbital ..................................................................................................................................................................................... Sufentanil ......................................................................................................................................................................................... Tapentadol ....................................................................................................................................................................................... Thebaine .......................................................................................................................................................................................... 96,750,000 91,250,000 61,125,000 25,628 9,000,000 1,262,500 91,250 1,287,500 22,750,000 10,250,000 153,750,000 18,375,000 7,000,000 42,500,000 6 30 3 42,393,750 3 3,750 215,003 6,880 13,750,000 145,000,000 g g g g g g g g g g g g g g g g g g g g g g g g 15,100,000 4,200,000 44,800,000 6,100,000 246,000,000 g g g g g mstockstill on DSK4VPTVN1PROD with NOTICES List I Chemicals Ephedrine (for conversion) .............................................................................................................................................................. Ephedrine (for sale) ......................................................................................................................................................................... Phenylpropanolamine (for conversion) ............................................................................................................................................ Phenylpropanolamine (for sale) ....................................................................................................................................................... Pseudoephedrine (for sale) ............................................................................................................................................................. VerDate Mar<15>2010 17:03 Aug 06, 2013 Jkt 229001 PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 E:\FR\FM\07AUN1.SGM 07AUN1 Federal Register / Vol. 78, No. 152 / Wednesday, August 7, 2013 / Notices Aggregate production quotas for all other Schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero. Dated: August 1, 2013. Thomas M. Harrigan, Deputy Administrator. [FR Doc. 2013–19046 Filed 8–6–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF LABOR Employment and Training Administration Comment Request for Information Collection for Job Corps Placement and Assistance Record, Extension Without Revisions Employment and Training Administration (ETA), Labor. ACTION: Notice. AGENCY: The Department of Labor (Department), as part of its continuing effort to reduce paperwork and respondent burden, conducts a preclearance consultation program to provide the general public and Federal agencies with an opportunity to comment on proposed and/or continuing collections of information in accordance with the Paperwork Reduction Act of 1995 (PRA95) [44 U.S.C. 3506(c)(2)(A)]. This program helps ensure that requested data can be provided in the desired format, reporting burden (time and financial resources) is minimized, collection instruments are clearly understood, and the impact of collection requirements on respondents can be properly assessed. Currently, ETA is soliciting comments concerning the collection of data about Job Corps Placement Record [OMB Control No. 1205–0035, expires January 2014]: ETA 678 form, Job Corps Placement and Assistance Record. ETA form 678 currently captures information about a student’s training and subsequent placement in a job, higher education or the military, as well as the name of the placement provider agency. Data generated from the form ETA 678 is used to evaluate overall placement outcomes. This form is critical to the program’s evaluation process. It is the only form which documents a student’s post-center placement status. This form is completed by either a Job Corps center records staff or a Career Transition Specialist for each student. Job Corps is not proposing any changes to ETA 678 form, Job Corps Placement Record. A copy of the proposed Information Collection Request (ICR) can be mstockstill on DSK4VPTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 17:03 Aug 06, 2013 Jkt 229001 obtained by contacting the office listed below in the addressee section of this notice. Written comments must be submitted to the office listed in the addressee’s section below on or before October 7, 2013. ADDRESSES: Submit written comments to Marcus Gray, Office of Job Corps, Room N–4463, Employment and Training Administration, U.S. Department of Labor, 200 Constitution Avenue NW., Washington, DC 20210. Telephone number: 202–693–3967 (this is not a toll-free number). Individuals with hearing or speech impairments may access the telephone number above via TTY by calling the toll-free Federal Information Relay Server at 877–889– 5627 (TTY/TDD). Fax: 202–693–2767; email: gray.marcus@dol.gov. A copy of the proposed ICR can be obtained by contacting the person listed above. SUPPLEMENTARY INFORMATION: DATES: I. Background Job Corps is the nation’s largest residential, educational, and career technical training program for young Americans. Job Corps was established in 1964 by the Economic Opportunity Act, and currently is authorized by Title I– C of the Workforce Investment Act of 1998. For almost 50 years, Job Corps has helped prepare a total of nearly 3 million at-risk young people ages 16 to 24 for success in our nation’s workforce. With 125 centers in 48 states, Puerto Rico, and the District of Columbia, Job Corps assists students across the nation in attaining academic credentials, including a High School Diploma (HSD) and/or High School Equivalency credential, and career technical training, including industry-recognized credentials, state licensures, and preapprenticeship credentials. Job Corps is administered by the Department through the Office of Job Corps and six Regional Offices. The Department awards and administers contracts for the recruiting and screening of new students, center operations, and the placement and transitional support of graduates and former enrollees. Large and small corporations and nonprofit organizations manage and operate 97 Job Corps centers under contractual agreements with the Department. These contract Center Operators are selected through a competitive procurement process that evaluates potential operators’ technical expertise, proposed costs, past performance, and other factors, in accordance with the PO 00000 Frm 00063 Fmt 4703 Sfmt 9990 48197 Competition in Contracting Act and the Federal Acquisition Regulations. The remaining 28 Job Corps centers, called Civilian Conservation Centers, are operated by the U.S. Forest Service, via an interagency agreement. The Department has a direct role in the operation of Job Corps, and does not serve as a pass-through agency for this program. II. Review Focus The Department is particularly interested in comments which: • Evaluate whether the proposed collection of information is necessary for the proper performance of the agency’s function, including whether the information has practical utility; • Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; • Enhance the quality, utility, and clarity of the information to be collected; and • Minimize the burden of the collection of information on those who are to respond, by encouraging the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses. III. Current Actions Type of Review: Extension Title: Job Corps Placement Record OMB Number: Control No. 1205–0035 Affected Public: Individuals or Households (Job Corps students) and Private Sector—(Job Corps centers) Form(s): ETA 678 Total Annual Respondents: 34,000 Annual Frequency: Once (when placement occurs) Total Annual Responses: 34,000 Average Time per Response: 7.43 minutes Estimated Total Annual Burden Hours: 4,210 Total Annual Other Burden Costs for Respondents: $0 Comments submitted in response to this comment request will be summarized and included in the request for Office of Management and Budget approval of the information collection request; they will also become a matter of public record. Dated: July 31, 2013. Eric M. Seleznow, Acting Assistant Secretary. [FR Doc. 2013–19061 Filed 8–6–13; 8:45 am] BILLING CODE 4510–FT–P E:\FR\FM\07AUN1.SGM 07AUN1

Agencies

[Federal Register Volume 78, Number 152 (Wednesday, August 7, 2013)]
[Notices]
[Pages 48193-48197]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-19046]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-365]


Final Adjusted Aggregate Production Quotas for Schedule I and II 
Controlled Substances and Assessment of Annual Needs for the List I 
Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2013

AGENCY: Drug Enforcement Administration (DEA), Department of Justice.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice establishes final adjusted 2013 aggregate 
production quotas for controlled substances in Schedules I and II of 
the Controlled Substances Act (CSA) and assessment of annual needs for 
the List I chemicals ephedrine, pseudoephedrine, and 
phenylpropanolamine, as well as the 2013 aggregate production quotas 
for three recently temporarily controlled substances.

FOR FURTHER INFORMATION CONTACT: John W. Partridge, Executive 
Assistant, Office of Diversion Control, Drug Enforcement 
Administration, 8701 Morrissette Drive, Springfield, VA 22152, 
Telephone: (202) 307-7165.

SUPPLEMENTARY INFORMATION:

Background

    Section 306 of the CSA (21 U.S.C. 826) requires the Attorney 
General to establish aggregate production quotas for each basic class 
of controlled substance listed in Schedules I and II and for ephedrine, 
pseudoephedrine, and phenylpropanolamine. This responsibility has been 
delegated to the Administrator of the DEA through 28 CFR 0.100. The 
Administrator, in turn, has redelegated this function to the Deputy 
Administrator, pursuant to 28 CFR 0.104. DEA published the 2013 
established aggregate production quotas for controlled substances in 
Schedules I and II and assessment of annual needs for the List I 
chemicals ephedrine, pseudoephedrine, and phenylpropanolamine in the 
Federal Register (77 FR 59980) on October 1, 2012. That notice stated 
that the Deputy Administrator would adjust, as needed, the established 
aggregate production quotas in 2013 as provided for in 21 CFR 1303.13 
and 21 CFR 1315.13. The 2013 proposed adjusted aggregate production 
quotas for controlled substances in Schedules I and II and assessment 
of annual needs for the List I chemicals ephedrine, pseudoephedrine, 
and phenylpropanolamine were subsequently published in the Federal 
Register on June 20, 2013, (78 FR 37237) in consideration of the 
outlined criteria. All interested persons were invited to comment on or 
object to the proposed adjusted aggregate production quotas and 
assessment of annual needs on or before July 22, 2013.

Analysis for Final Adjusted 2013 Aggregate Production Quotas and 
Assessment of Annual Needs

    Consideration has been given to the criteria outlined in the June 
20, 2013, notice of proposed adjusted aggregate production quotas and 
assessment of annual needs, in accordance with 21 CFR 1303.13 and 21 
CFR 1315.13. Six companies submitted timely comments regarding a total 
of 30 Schedule I and II controlled substances. Comments received 
proposed that the aggregate production quotas for 2-(2,5-Dimethoxy-4-
(n)-propylphenyl)ethanamine (2C-P); 2-(2,5-Dimethoxy-4-
ethylphenyl)ethanamine (2C-E); 2-(2,5-Dimethoxy-4-
methylphenyl)ethanamine (2C-D); 2-(2,5-Dimethoxy-4-nitro-
phenyl)ethanamine (2C-N); 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H); 2-
(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C); 2-(4-Iodo-2,5-
dimethoxyphenyl)ethanamine (2C-I); 2-[4-(Ethylthio)-2,5-
dimethoxyphenyl]ethanamine (2C-T-2); 2-[4-(Isopropylthio)-2,5-
dimethoxyphenyl]ethanamine (2C-T-4); 3,4-Methylenedioxymethamphetamine 
(MDMA); 4-Anilino-N-phenethyl-4-piperidine (ANPP); amphetamine (for 
sale); codeine (for conversion); dihydromorphine; diphenoxylate (for 
sale); gamma hydroxybutyric acid; hydrocodone; hydromorphone; 
levomethorphan; methadone; methadone intermediate; methylphenidate; 
morphine (for conversion); morphine (for sale); oxycodone (for sale); 
oripavine; oxymorphone (for conversion); oxymorphone (for sale); 
phenylacetone; and sufentanil were insufficient to provide for the 
estimated medical, scientific, research, and industrial needs of the 
United States, for export requirements, and for the establishment and 
maintenance of reserve stocks. One manufacturer commented that the APQ 
for thebaine was insufficient; however, that commenter was referring to 
a need for procurement quota for thebaine, which does not directly 
impact the APQ and, thus, was not considered. DEA did not previously 
propose adjustments to the 2013 assessment of annual needs for 
ephedrine, pseudoephedrine, and phenylpropanolamine and received no 
comments concerning such.
    DEA has taken into consideration the above comments along with the 
relevant 2012 year-end inventories, initial 2013 manufacturing quotas 
and import quotas, 2013 export requirements, actual and projected 2013 
sales, research and product development requirements, and additional 
applications received. Based on all of the above, the Deputy 
Administrator has determined that the proposed adjusted 2013 aggregate 
production quotas and assessment of annual needs for dihydromorphine; 
diphenoxylate (for sale); gamma hydroxybutyric acid; hydromorphone; 
levomethorphan; morphine (for sale); oxymorphone (for sale); 
phenylacetone; psilocyn; sufentanil; ephedrine (for sale); 
phenylpropanolamine (for conversion); and pseudoephedrine (for sale) 
required additional consideration and hereby further adjusts the 2013 
aggregate production quotas for those substances.
    Regarding 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P); 2-
(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E); 2-(2,5-Dimethoxy-4-
methylphenyl)ethanamine (2C-D); 2-(2,5-Dimethoxy-4-nitro-
phenyl)ethanamine (2C-N); 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);

[[Page 48194]]

2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C); 2-(4-Iodo-2,5-
dimethoxyphenyl)ethanamine (2C-I); 2-[4-(Ethylthio)-2,5-
dimethoxyphenyl]ethanamine (2C-T-2); 2-[4-(Isopropylthio)-2,5-
dimethoxyphenyl]ethanamine (2C-T-4); 3,4-Methylenedioxymethamphetamine 
(MDMA); 4-Anilino-N-phenethyl-4-piperidine (ANPP); amphetamine (for 
sale); codeine (for conversion); hydrocodone; methadone; methadone 
intermediate; methylphenidate; morphine (for conversion); oxycodone 
(for sale); oripavine; and oxymorphone (for conversion), the Deputy 
Administrator hereby determines that the proposed adjusted 2013 
aggregate production quotas and assessment of annual needs for these 
substances and List I chemicals as published on June 20, 2013, (78 FR 
37237) are sufficient to meet the current 2013 estimated medical, 
scientific, research, and industrial needs of the United States and to 
provide for adequate inventories.
    As described in the previously published notice establishing the 
2013 aggregate production quotas and assessment of annual needs, DEA 
has specifically considered that inventory allowances granted to 
individual manufacturers may not always result in the availability of 
sufficient quantities to maintain an adequate reserve stock pursuant to 
21 U.S.C. 826(a), as intended. See 21 CFR 1303.24. This would be 
concerning if a natural disaster or other unforeseen event resulted in 
substantial disruption to the amount of controlled substances available 
to provide for legitimate public need. As such, DEA has included in all 
proposed revised Schedule II aggregate production quotas, and certain 
Schedule I aggregate production quotas, an additional 25% of the 
estimated medical, scientific, and research needs as part of the amount 
necessary to ensure the establishment and maintenance of reserve 
stocks. The resulting adjusted established aggregate production quotas 
will reflect these included amounts. This action will not affect the 
ability of manufacturers to maintain inventory allowances as specified 
by regulation. DEA expects that maintaining this reserve in certain 
established aggregate production quotas will mitigate adverse public 
effects if an unforeseen event resulted in substantial disruption to 
the amount of controlled substances available to provide for legitimate 
public need, as determined by DEA. DEA does not anticipate utilizing 
the reserve in the absence of these circumstances.
    Pursuant to the above, the Deputy Administrator hereby finalizes 
the 2013 aggregate production quotas for the following Schedule I and 
II controlled substances and the 2013 assessment of annual needs for 
the List I chemicals ephedrine, pseudoephedrine, and 
phenylpropanolamine, expressed in grams of anhydrous acid or base, as 
follows:

------------------------------------------------------------------------
                                                         Final adjusted
                      Basic class                          2013 quotas
------------------------------------------------------------------------
                    Temporarily Scheduled Substances
------------------------------------------------------------------------
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-                                   15 g
 tetramethylcyclopropyl)methanone (UR-144)............
[1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-                        15 g
 tetramethylcyclopropyl)methanone (XLR11).............
N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide                  15 g
 (AKB48)..............................................
------------------------------------------------------------------------
                               Schedule I
------------------------------------------------------------------------
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201).....              45 g
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)....              45 g
1-[1-(2-Thienyl)cyclohexyl]piperidine.................               5 g
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-              45 g
 200).................................................
1-Butyl-3-(1-naphthoyl)indole (JWH-073)...............              45 g
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-              45 g
 18 and RCS-8)........................................
1-Hexyl-3-(1-naphthoyl)indole (JWH-019)...............              45 g
1-Methyl-4-phenyl-4-propionoxypiperidine..............               2 g
1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678)....              45 g
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).....              45 g
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)....              45 g
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398).....              45 g
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122).....              45 g
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4).              45 g
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081)...              45 g
2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P).              15 g
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)......              15 g
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D).....              15 g
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N).....              15 g
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)..............              15 g
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C).....              15 g
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I).......              15 g
2,5-Dimethoxy-4-ethylamphetamine (DOET)...............              12 g
2,5-Dimethoxy-4-n-propylthiophenethylamine............              12 g
2,5-Dimethoxyamphetamine..............................              12 g
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-              15 g
 2)...................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine                 15 g
 (2C-T-4).............................................
3,4,5-Trimethoxyamphetamine...........................              12 g
3,4-Methylenedioxyamphetamine (MDA)...................              30 g
3,4-Methylenedioxymethamphetamine (MDMA)..............              50 g
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)..........              24 g
3,4-Methylenedioxy-N-methylcathinone (methylone)......              35 g
3,4-Methylenedioxypyrovalerone (MDPV).................              25 g
3-Methylfentanyl......................................               2 g
3-Methylthiofentanyl..................................               2 g

[[Page 48195]]

 
4-Bromo-2,5-dimethoxyamphetamine (DOB)................              12 g
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)............              12 g
4-Methoxyamphetamine..................................              88 g
4-Methyl-2,5-dimethoxyamphetamine (DOM)...............              25 g
4-Methylaminorex......................................              12 g
4-Methyl-N-methylcathinone (mephedrone)...............              25 g
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-             68 g
 phenol...............................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-              53 g
 phenol (cannabicyclohexanol or CP-47, 497 C8-homolog)
5-Methoxy-3,4-methylenedioxyamphetamine...............              12 g
5-Methoxy-N,N-diisopropyltryptamine...................              12 g
5-Methoxy-N,N-dimethyltryptamine......................              10 g
Acetyl-alpha-methylfentanyl...........................               2 g
Acetyldihydrocodeine..................................               2 g
Acetylmethadol........................................               2 g
Allylprodine..........................................               2 g
Alphacetylmethadol....................................               2 g
Alpha-ethyltryptamine.................................              12 g
Alphameprodine........................................               2 g
Alphamethadol.........................................               2 g
Alpha-methylfentanyl..................................               2 g
Alpha-methylthiofentanyl..............................               2 g
Alpha-methyltryptamine (AMT)..........................              12 g
Aminorex..............................................              12 g
Benzylmorphine........................................               2 g
Betacetylmethadol.....................................               2 g
Beta-hydroxy-3-methylfentanyl.........................               2 g
Beta-hydroxyfentanyl..................................               2 g
Betameprodine.........................................               2 g
Betamethadol..........................................               2 g
Betaprodine...........................................               2 g
Bufotenine............................................               3 g
Cathinone.............................................              12 g
Codeine-N-oxide.......................................             602 g
Desomorphine..........................................               5 g
Diethyltryptamine.....................................              12 g
Difenoxin.............................................              50 g
Dihydromorphine.......................................       3,990,000 g
Dimethyltryptamine....................................              18 g
Gamma-hydroxybutyric acid.............................      67,500,000 g
Heroin................................................              25 g
Hydromorphinol........................................              54 g
Hydroxypethidine......................................               2 g
Ibogaine..............................................               5 g
Lysergic acid diethylamide (LSD)......................              30 g
Marihuana.............................................          21,000 g
Mescaline.............................................              13 g
Methaqualone..........................................              10 g
Methcathinone.........................................              14 g
Methyldihydromorphine.................................               2 g
Morphine-N-oxide......................................             655 g
N,N-Dimethylamphetamine...............................              12 g
N-Benzylpiperazine....................................              15 g
N-Ethylamphetamine....................................              12 g
N-Hydroxy-3,4-methylenedioxyamphetamine...............              12 g
Noracymethadol........................................               2 g
Norlevorphanol........................................              52 g
Normethadone..........................................               2 g
Normorphine...........................................              18 g
Para-fluorofentanyl...................................               2 g
Phenomorphan..........................................               2 g
Pholcodine............................................               2 g
Properidine...........................................               2 g
Psilocybin............................................              10 g
Psilocyn..............................................              12 g
Tetrahydrocannabinols.................................         491,000 g
Thiofentanyl..........................................               2 g
Tilidine..............................................              10 g
Trimeperidine.........................................               2 g
------------------------------------------------------------------------
                               Schedule II
------------------------------------------------------------------------
1-Phenylcyclohexylamine...............................               3 g
1-Piperdinocyclohexanecarbonitrile....................              21 g

[[Page 48196]]

 
4-Anilino-N-phenethyl-4-piperidine (ANPP).............       2,250,000 g
Alfentanil............................................          38,250 g
Alphaprodine..........................................               3 g
Amobarbital...........................................               9 g
Amphetamine (for conversion)..........................      22,875,000 g
Amphetamine (for sale)................................      47,186,000 g
Carfentanil...........................................               6 g
Cocaine...............................................         240,000 g
Codeine (for conversion)..............................      81,250,000 g
Codeine (for sale)....................................      49,506,250 g
Dextropropoxyphene....................................              19 g
Dihydrocodeine........................................         250,000 g
Diphenoxylate.........................................         887,500 g
Ecgonine..............................................         144,000 g
Ethylmorphine.........................................               3 g
Fentanyl..............................................       2,108,750 g
Glutethimide..........................................               3 g
Hydrocodone (for sale)................................      99,625,000 g
Hydromorphone.........................................       6,750,000 g
Isomethadone..........................................               5 g
Levo-alphacetylmethadol (LAAM)........................               4 g
Levomethorphan........................................             195 g
Levorphanol...........................................           4,500 g
Lisdexamfetamine......................................      21,000,000 g
Meperidine............................................       6,875,000 g
Meperidine Intermediate-A.............................               6 g
Meperidine Intermediate-B.............................              11 g
Meperidine Intermediate-C.............................               6 g
Metazocine............................................               6 g
Methadone (for sale)..................................      33,125,000 g
Methadone Intermediate................................      40,500,000 g
Methamphetamine.......................................       3,912,500 g
------------------------------------------------------------------------
[987,500 grams of levo-desoxyephedrine for use in a non-controlled, non-
 prescription product; 2,863,750 grams for methamphetamine mostly for
 conversion to a schedule III product; and 61,250 grams for
 methamphetamine (for sale)]
------------------------------------------------------------------------
Methylphenidate.......................................      96,750,000 g
Morphine (for conversion).............................      91,250,000 g
Morphine (for sale)...................................      61,125,000 g
Nabilone..............................................          25,628 g
Noroxymorphone (for conversion).......................       9,000,000 g
Noroxymorphone (for sale).............................       1,262,500 g
Opium (powder)........................................          91,250 g
Opium (tincture)......................................       1,287,500 g
Oripavine.............................................      22,750,000 g
Oxycodone (for conversion)............................      10,250,000 g
Oxycodone (for sale)..................................     153,750,000 g
Oxymorphone (for conversion)..........................      18,375,000 g
Oxymorphone (for sale)................................       7,000,000 g
Pentobarbital.........................................      42,500,000 g
Phenazocine...........................................               6 g
Phencyclidine.........................................              30 g
Phenmetrazine.........................................               3 g
Phenylacetone.........................................      42,393,750 g
Racemethorphan........................................               3 g
Remifentanil..........................................           3,750 g
Secobarbital..........................................         215,003 g
Sufentanil............................................           6,880 g
Tapentadol............................................      13,750,000 g
Thebaine..............................................     145,000,000 g
------------------------------------------------------------------------
                            List I Chemicals
------------------------------------------------------------------------
Ephedrine (for conversion)............................      15,100,000 g
Ephedrine (for sale)..................................       4,200,000 g
Phenylpropanolamine (for conversion)..................      44,800,000 g
Phenylpropanolamine (for sale)........................       6,100,000 g
Pseudoephedrine (for sale)............................     246,000,000 g
------------------------------------------------------------------------


[[Page 48197]]

    Aggregate production quotas for all other Schedule I and II 
controlled substances included in 21 CFR 1308.11 and 1308.12 remain at 
zero.

    Dated: August 1, 2013.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2013-19046 Filed 8-6-13; 8:45 am]
BILLING CODE 4410-09-P